What are the adverse reactions of osimertinib/osimertinib?

Osimertinib is a targeted treatment for non-small cell lung cancer (NSCLC). Although it has shown significant efficacy in treatment, it may also cause a series of adverse reactions. The following are common and serious adverse reactions that may occur with osimertinib/osimertinib:

1.Skin toxicity: Osimertinib/Osimertinib can cause skin reactions such as rash, itching, dryness and scaling. Skin redness, blisters, ulcers, and drug-related dermatitis may also sometimes occur. These skin reactions are usually mild, but in some patients they can severely affect quality of life.

2.Gastrointestinal discomfort: Gastrointestinal symptoms including nausea, vomiting, diarrhea and indigestion are common adverse reactions during osimertinib/osimertinib treatment. These discomforts are usually mild to moderate but may severely affect appetite and nutrient absorption in some patients.

3.Pulmonary toxicity: Osimertinib/Osimertinib may cause pulmonary toxic reactions, including cough, dyspnea, lung inflammation and alveolar hemorrhage. These reactions may be manifestations of treatment-related pneumonitis or interstitial lung disease and require prompt monitoring and management.

4.Adverse cardiovascular events: Osimertinib/Osimertinib treatment may cause adverse cardiovascular events, such as arrhythmia, hypertension, myocardial damage and heart failure. Patients need regular monitoring of electrocardiogram and heart function, as well as blood pressure control during treatment.

5.Visual impairment: Osimertinib/OsimertinibTreatment may cause visual disturbances such as blurred vision, dry eyes, light sensitivity, and eye pain. Patients should seek medical treatment promptly when these symptoms occur and adjust their treatment plan according to the doctor's recommendations.

6.Abnormal liver function: Some patients may develop abnormal liver function after receiving osimertinib/osimertinib treatment, manifested as elevated liver enzymes, jaundice and liver damage. Therefore, liver function needs to be monitored regularly and corresponding measures taken when abnormalities occur.

7.Immune system reaction: Osimertinib/OsimertinibTreatment may trigger immune system reactions, including allergic reactions, skin inflammation, and Sjogren's syndrome. Patients should pay close attention to physical discomfort while receiving treatment and seek medical advice promptly for evaluation and treatment.

8.Hematological abnormalities: Osimertinib/OsimertinibTreatment may cause blood system abnormalities, such as leukopenia, thrombocytopenia, and anemia. Patients need to regularly monitor blood indicators during treatment and take appropriate measures when abnormalities occur.

9.Other adverse reactions: There are some other possible adverse reactions, such as headache, joint pain, muscle pain, fatigue and weight loss. These reactions are usually mild but may be significant in some patients.

In general, Osimertinib/Osimertinib, as a targeted therapy, may have a variety of adverse reactions during the treatment of NSCLC. Patients should pay close attention to their physical condition when receiving treatment, conduct relevant examinations and monitoring regularly, and promptly report any symptoms of discomfort to the doctor so that the treatment plan can be adjusted and corresponding measures taken to ensure the safety and effectiveness of the treatment.